Shift Bioscience is a biotech company using generative AI models to understand how activation of different genes can reverse the aging process. This research is a fundamental step forward in designing more effective drugs to treat age-related diseases.
From Shift BioscienceOct 16 2024 Today the company announced that it has raised $16 M in Seed funding, led by BGF, with existing investors F-Prime Capital, Kindred Capital, and Jonathan Milner participating. The investment will be used for the continued development of Shift Bioscience’s artificial intelligence cell simulation platform, for the identification of genes that can safely rejuvenate cells to combat the effects of age-related illnesses.
Average life expectancy has increased over the last century, which has led to a rise in the number of people suffering from age-related illnesses, increasing the strain on healthcare systems. Cellular reprogramming with Yamanaka factors represents a promising technology that can rejuvenate cells, providing the opportunity to develop new treatments that target multiple diseases of aging, from hearing loss to cardiovascular disease and osteoarthritis.
“Our technology is addressing the current limitations of cellular reprogramming for treatment of age-related illnesses,” Dr Daniel Ives, CEO, Shift Bioscience, commented. “This investment is indicative of the strength of our approach and is one of the earliest funding rounds for a biotech start-up exclusively focused on the rapidly emerging field of cell simulation for target discovery.
Shift Bioscience is building a cell simulation platform that combines generative AI with its highly accurate, high-throughput biological aging clock, to predict which sets of genes are most likely to safely rejuvenate specific cells and then test, improve and validate these predictions. Preliminary results from the platform were well received at the 2024 Gordon Research Conference on Systems Aging.
We’re excited to be backing a British company at the forefront of developing a new class of regenerative medicines. Combining machine learning with lab-based biology, Shift’s well-developed platform represents a significant opportunity to address the growing challenges of treating age-related disease and illnesses.”
Aging Artificial Intelligence Drugs Genes Research Technology
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
UAE's Oil Giant ADNOC to Buy Chemicals Firm Covestro in $16-Billion DealAbu Dhabi National Oil Company ADNOC has agreed to acquire German chemicals giant Covestro in a $16.3 billion deal.
Read more »
UK Car Factories Gear Up for Electric ShiftUK car production fell in August due to a combination of factors, including summer shutdowns, model changes, and a shift towards electric vehicle production, but the industry remains optimistic about future growth.
Read more »
Man United can prove intriguing tactical shift is no fluke against TottenhamMan Utd face Tottenham at Old Trafford on Sunday in what is already shaping up to be a crucial fixture in the race for Champions League places.
Read more »
Vance Outperformed Walz in a Debate Unlikely to Shift the RaceA polished J.D. Vance never broke a sweat while Tim Walz struggled.
Read more »
Ownership battles could shift British press further to the rightWatch out as a new cast of moguls prepare to step on to the media stage even though some shun the spotlight
Read more »
Triton avoids share suspension with new Mozambique missionFormer graphite hopeful finds reason to stick around on the ASX with copper-gold shift
Read more »